Live
- BJP MP candidate Bharat Prasad visited the student who tried to commit suicide
- PM’s popularity in the fast lane: Autos with 'Har Dil Mein Modi' slogan spotted across Delhi
- Delhi-based political parties are like East India Company: Sukhbir Badal
- Golf: Diksha moves into Top-20 at South African Women’s Open
- KCR lashes out against BJP and Congress for destroying Telangana
- Dairy Science students visited the Milk cooling plant
- Moody feels Pant ahead in keepers’ race for T20 WC squad; Srikkanth picks Rahul over Samson as reserve keeper
- Thanking voters for extending 'unparalleled support' to NDA, PM Modi says second phase 'too good'
- Natural Relief for Menstrual Cramps: Beetroot Juice Recipe
- Asha Worker died in a road accident
Dr. Reddy's gets USFDA approval for doxorubicin hydrochloride liposome injection
Pharma major Dr. Reddy\'s Laboratories Ltd has received approval from the US Food and Drug Administration (USFDA) to launch doxorubicin hydrochloride liposome injection, for intravenous use, in the US market.
Hyderabad: Pharma major Dr. Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration (USFDA) to launch doxorubicin hydrochloride liposome injection, for intravenous use, in the US market.
Doxorubicin hydrochloride liposome injection is a therapeutic equivalent generic version of Doxil® (doxorubicin hydrochloride liposome injection).
The USFDA approval is an outcome of extensive collaboration with the company's partner, Natco Pharma Ltd. on R&D and manufacturing capabilities, the Hyderabad-based Dr Reddy's said in a statement on Wednesday.
"This approval represents the first of its kind for Dr. Reddy's in the complex depot injectables arena," explains Alok Sonig, Executive Vice President and Head of the North America Generics business at Dr. Reddy's Laboratories.
"It is a testament to our commitment to bring affordable generic medicines to market for patients. The approval further validates our capabilities to successfully develop and manufacture complex liposomal formulations. We are preparing for a commercial launch soon," he said.
The Doxil® brand and generic had US sales of approximately $196 million MAT (moving annual total) for the recent 12 months ending in March 2017, according to IMS Health.
Doxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion in 10-ml or 30-ml glass, single-dose vials.
